AETHLON MEDICAL INC

Aethlon Medical is advancing its Hemopurifier, a clinical-stage immunotherapeutic device with FDA "Breakthrough Device" designation for oncology and life-threatening infectious diseases. The company is progressing with a safety, feasibility, and dose-finding clinical trial in Australia for advanced/metastatic cancer patients, having completed the first two cohorts without serious adverse events. To support operations and clinical development, Aethlon recently raised approximately $1.9 million in gross proceeds through an at-the-market (ATM) offering. However, the company's financial statements for fiscal year 2026 carry a going concern qualification, highlighting the need for additional financing and the speculative nature of investment.

Aethlon Medical, Inc. announced its financial results for the fiscal year ended March 31, 2026, reporting a reduced net loss of $7.2 million compared to $13.4 million in the prior year, alongside a 21.9% decrease in operating expenses to $7.3 million. Key business updates include advancing their Australian oncology study into the final dosing cohort and strengthening the Hemopurifier intellectual property portfolio with new patents for coronavirus-related conditions. The company also reported $5.0 million in cash and cash equivalents as of March 31, 2026.